Original news and analysis on international IP policy
The 15th IP Law Summit, produced by Marcus Evans, is scheduled for 21-23 March in Colorado Springs, Colorado, US. Gathering corporate senior IP Counsel together with service providers, the Summit will offer a focused discussion of cutting-edge technology, strategy and products driving the IP marketplace.
On the occasion of the 132nd session of the World Health Organization Executive Board last week, delegations welcomed the efforts made by the international community to eradicate poliomyelitis (polio), but saw room for improvement. As a way forward, they looked to the key role played by WHO partners.
The European Commission's claims of support for development cooperation contrast with budget cuts for aid, raising doubts about the EU’s real will and ability to address today’s overall challenges and push for inclusive and sustainable development, writes Daniele Dionisio.
The World Health Assembly’s rotating Executive Board meets twice a year, and on 29 January concluded its 132nd meeting with what the WHO director general termed an “unprecedented” amount of agenda items and documents.
Prof. Ryan Abbott analyzes the key components of the WHO proposal for a Global R&D Treaty and their potential impact on public health. The article proposes strategies to convert parties currently opposing the treaty, and argues that a stratified limited market-exclusivity regime has the capacity for a meaningful impact.
The World Health Organization Executive Board today approved a modified resolution on neglected tropical diseases – after removing a reference to a working group on R&D for neglected diseases as “irrelevant”. The Board also discussed and took note of a report on poor quality medical products in the supply chain, and agreed to set another meeting on the issue before the May World Health Assembly, as well as set up a separate group on behaviours that lead to this problem.
World Health Organization members on Friday held a tense discussion over legal and political aspects of a consensus reached by a small number of member states in November on implementing a plan to address the global lack of research and development for neglected diseases predominantly afflicting poor populations. The discussion may continue today, with the linkage of an agenda item on neglected tropical diseases and the report of an expert working group offering numerous ideas for addressing the problem.
The World Health Organization has not completed negotiations with companies on a formula for contribute toward the new WHO framework for pandemic influenza. But companies are paying to access the virus anyway. In its meeting this week, the WHO Executive Board has addressed a range of issues such as pandemic influenza, but so far it has delayed discussion on another contentious topic: substandard/counterfeit medical products.
UNITAID, the drug purchasing facility affiliated with the World Health Organization, sees "great promise" in emerging diagnostic products for HIV treatment monitoring and diagnosis in remote regions. Now it is looking for someone to verify the freedom to operate of these tools, ensuring they are not intellectual property-encumbered.
India has started the New Year on a volatile note. With general elections looming in 2014, there is turbulence and not just in the political world. In India’s pharmaceutical industry, there is sparring over the prickly issue of ‘compulsory licenses’, a mechanism by which a government allows a domestic company to manufacture and sell a generic version of a patented drug without the consent of the patent-holder, who receives compensation.
World Health Organization Director General Margaret Chan today opened the 132nd meeting of the Executive Board, the UN agency’s highest authority, emphasising the importance of cost-effectiveness and results-driven operations at a time of global economic austerity and precarious funding.
The United States Federal Trade Commission, which keeps an eye out for anticompetitive behaviour, has issued a study finding that in 2012, a record number of deals were struck between brand-name and generic drug companies to keep the lower-priced generics off the market. Such deals, which arise from patent disputes, cost American consumers billions of dollars annually while piling on the federal deficit, it said.